Bladder cancer trial explores immunotherapy cocktails to fight recurrence
Disease control
Ongoing
This phase 1/2 trial tests the immunotherapy drug durvalumab alone or combined with other treatments (BCG, radiation, or chemotherapy) in 55 people with non-muscle invasive bladder cancer. The goal is to find safe doses and see if these combinations can eliminate cancer and preve…
Phase: PHASE1, PHASE2 • Sponsor: Noah Hahn, M.D. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC